Close Window
Aetna Aetna
Clinical Policy Bulletin:
Esophageal and Airway pH Monitoring
Number: 0667


  1. Aetna considers esophageal pH monitoring medically necessary for any of the following indications:

    1. To detect refractory reflux in members with chest pain after cardiac evaluation using a symptom reflux association scheme, preferably the symptom association probability calculation (pH study done after a trial of proton pump inhibitor [PPI] therapy for at least 4 weeks); or
    2. To document abnormal esophageal acid exposure in an endoscopy-negative member being considered for surgical anti-reflux repair (pH study done after withholding anti-secretory drug regimen for more than 1 week); or
    3. To document concomitant gastro-esophageal reflux disease (GERD) in an adult onset, non-allergic asthmatic suspected of having reflux-induced asthma (pH study done after withholding anti-secretory drugs for more than 1 week).  Note: a positive test does not prove causality; or
    4. To evaluate a member with suspected otolaryngologic manifestations (chronic cough, laryngitis, pharyngitis) of GERD after symptoms have failed to respond to at least 4 weeks of PPI therapy (pH study done while the member continues taking their anti-secretory drug regimen to document the adequacy of therapy); or
    5. To evaluate vomiting in infants up to 3 months of age; or
    6. To evaluate members after anti-reflux surgery who are suspected to have ongoing abnormal reflux (pH study done after withholding anti-secretory drug regimen for more than 1 week); or
    7. To evaluate members with either normal or equivocal endoscopic findings and reflux symptoms that are refractory to PPI therapy (pH study done after withholding anti-secretory drug regimen for 1 week or more if the study is done to confirm excessive acid exposure or while taking the anti-secretory drug regimen if symptom-reflux correlation is to be scored).

    The disposable capsule pH monitor (Bravo pH Monitoring System) is considered an acceptable alternative to standard catheter-based ambulatory pH monitoring for the medically necessary indications listed above except for evaluating vomiting for infants. The Bravo pH Monitoring System is considered experimental and investigational for evaluating vomiting in infants because it has not been approved for use in this age group.

  2. Aetna considers esophageal pH recording experimental and investigational for all other indications, including any of the following indications because its effectiveness for these indications has not been established:

    1. To detect or verify reflux esophagitis (this is an endoscopic diagnosis); or
    2. To evaluate “alkaline reflux”; or
    3. To evaluate apnea of prematurity in infants; or
    4. To titrate PPI dosing in the management of Barrett's esophagus. 
  3. Aetna considers airway pH monitoring for detection of laryngo-pharyngeal reflux and other indications experimental and investigational because its effectiveness for these indications has not been established.

  4. Aetna considers multichannel intraluminal impedance in combination with pH monitoring in the evaluation of GERD experimental and investigational because there is inadequate evidence in the peer-reviewed published clinical literature regarding its effectiveness.


This policy is mainly based upon evidence-based guidelines from the American Gastroenterological Association (AGA, 2001).

Esophageal pH recording provides quantitative data on both esophageal acid exposure and on the correlation between patient symptoms and reflux events.  Despite these strengths, the inherent weakness of the technique is its inability to prove causality between symptoms and acid reflux.  Alternatively, causality is reasonably assumed in clinical practice by the alleviation of suspected reflux symptoms during a therapeutic trial of a proton pump inhibitor (PPI).  In view of this viable alternative, the AGA (2001) has concluded that the major indications for esophageal pH monitoring are in documenting the failure of either medical or surgical therapy.

For standard ambulatory esophageal pH monitoring, a nasogastric catheter fitted with a pH probe is inserted through the nose into the lower esophagus.  The catheter is attached to a data logger that is worn on the body.  The catheter is left in place for 24 to 48 hrs.  Over this period, the probe measures the amount of acid refluxing in the esophagus and the pattern of occurrence throughout the day.  The patient reports any symptoms, such as pain, waterbrash, wheezing and coughing, and their timing.  Some ambulatory pH monitors have a button for the patient to press when he/she is having symptoms in order to alert the physician reading the study that they were having symptoms at a particular time.  This helps the physician to determine if symptoms are related to acid reflux.

Because the use of a nasogastric catheter is awkward and distressing to the patient, a newer catheter-free approach has been developed (the Bravo pH Monitoring System, Medtronic, Minneapolis, MN) that uses a tiny disposable capsule pH monitor that is pinned to the lower esophagus via an endoscopic approach.  The capsule transmits pH data to a data logger that is worn on the body.  After several days, the disposable capsule is sloughed off the esophagus and passes out of the digestive tract.

An assessment of the evidence supporting catheterless esophageal pH monitoring by the National Institute for Health and Clinical Excellence (NICE, 2006) concluded that “[c]urrent evidence on the safety and efficacy of catheterless oesophageal pH monitoring appears adequate to support the use of this technique provided that normal arrangements are in place for consent, audit and clinical governance.”  The assessment noted that catheterless pH monitoring would be particularly appropriate in children and other patients who may not tolerate the nasal intubation required for catheter-based monitoring.  The assessment also noted that catheterless pH monitoring may be unsuitable for some patients, for example patients with pacemakers.

Dickman and Fass (2006) stated that "pH testing remains a commonly used evaluative tool in clinical practice.  However, the original tool that included a nasally placed pH catheter was plagued with a variety of shortcomings, primarily the effect of the procedure on patients' lifestyle and thus on reflux-provoking activities.  The miniaturization of evaluative techniques in gastroenterology was the impetus for the development of the wireless pH capsule and the SmartPill.  These modalities improve patients' tolerability of the required test and provide a unique opportunity for expansion of indications and data collection.  The introduction of the multi-channel intraluminal impedance with a pH sensor allowed the detection of gastroesophageal reflux (GER) that is non-acidic.  However, the value of the technique beyond the realm of academic gastroenterology remains to be elucidated.  Recently, there was a renewal of interest in Bilitec 2000.  The technique, which has never found a clear clinical role, has been recommended as an important tool in evaluating patients who failed PPI therapy.  However, data to support its clinical value in this situation have remained scant".

Wenner et al (2007) evaluated and compared the subjective experience of patients undergoing esophageal pH monitoring by means of the wireless pH capsule method or the conventional catheter-based method.  Using a randomized study design, patients referred for esophageal pH testing underwent both wireless and traditional catheter-based 24-hr pH recording with a 7-day interval.  The wireless pH capsule was placed during endoscopy and followed by 48-hr pH recording. All patients answered a questionnaire, including a 10-cm visual analog scale (VAS), which described the perceived severity of symptoms and the degree of interference with normal daily activities during the pH tests.  A total of 31 patients (16 women and 15 men) were included in the analysis.  The severity of all adverse symptoms associated with the wireless technique was significantly lower compared with the catheter-based technique (median VAS 2.1 versus 5.1, p < 0.001).  Wireless pH recording was associated with less interference with off-work activities and normal daily life, median VAS 0.6 and 0.7 compared with 5.0 and 5.7, respectively, for the catheter-based technique (p < 0.0001).  Patients actively working during both tests reported less interference with normal work during the capsule-based test than during the catheter-based pH test (median VAS 0.3 versus 6.8, p = 0.005).  Twenty-seven patients (87 %) stated that, if they had to undergo esophageal pH monitoring again, they preferred the wireless test over the catheter-based pH test (p < 0.0001).  The authors concluded that these findings showed that a significant majority of patients undergoing esophageal pH monitoring preferred the wireless pH capsule over the traditional catheter-based technique because of less adverse symptoms and less interference with normal daily life.

Davids and colleagues (2008) stated that laryngo-pharyngeal reflux (LPR) -- GER above the upper esophageal sphincter -- is a common problem encountered by otolaryngologists.  Despite consensus guidelines, the presentation, diagnosis, and treatment remain controversial.  These researchers surveyed Canadian otolaryngologists to assess current perspectives.  Web-based questionnaires were e-mailed to 135 otolaryngologists.  Respondents were categorized by subspecialty as head and neck (H&N) or non-H&N (rhinology, otology, laryngology, facial plastics, general and pediatric otolaryngology).  Data were analyzed to determine differences in proportions between groups.  The response rate was 48 of 135 otolaryngologists.  Symptoms considered to be strongly or moderately associated with LPR included globus sensation, excessive throat clearing, sore or burning throat, hoarseness, chronic cough, and dysphonia.  The laryngoscopic signs considered strongly associated with LPR were edema, intra-arytenoid changes, and granulomata.  The majority of otolaryngologists in both the H&N (12 of 15) and non-H&N groups (27 of 32) use flexible laryngoscopy for investigation and diagnosis of LPR.  Proton pump inhibitors in addition to lifestyle modifications are recommended by both groups as 1st- and 2nd-line therapy for an initial course of 6 to 12 weeks, with long-term therapy extended for 4 to 12 months.  The authors concluded that Canadian otolaryngologists do correlate specific signs and symptoms with LPR patients.  This is consistent across sub-specialties within the field.  Flexible fibre-optic laryngoscopy is the preferred diagnostic tool.  Although evidence based on randomized controlled trials has yet to demonstrate a reproducible, statistically significant improvement in LPR from treatment, 1st-line pharmacotherapy (in addition to lifestyle changes) is generally provided as a PPI, with the duration of therapy being somewhat variable and less than that recommended by the current literature.

Mel-S (2008) stated that LPR is a a widely recognized disorder in otolaryngological practice.  However, the signs and symptoms attributed to this disorder are non-specific and treatment is usually empirical.  The author noted that there is still much to learn about the pathophysiological mechanisms of LPR and there is still much controversy on diagnostic as well as therapeutic parameters for this condition.  There is no consensus on the diagnosis and treatment of LPR and the majority of clinicians depend mainly on clinical findings and empirical treatments rather than more specific investigations.  The author concluded that the concept of LPR is still controversial.  The current practice of empirical treatment with PPIs is based on weak evidence.  However, this practice seems to be widely accepted and will not change until further clinical and laboratory studies improve the understanding of this condition.

Gupta and Sataloff (2009) shared the same view on LPR as Mel-S (2008).  These investigators noted that despite numerous research efforts, the diagnosis and treatment of LPR remain elusive and unproven.  Acid-induced changes in laryngo-pharyngeal mucosa have been confirmed by histological evidence.  However, the implications of this for laryngeal signs and symptoms are unclear.  Diagnosis remains controversial, confounded by a lack of standardization and accepted evidence-based norms.  Whereas treatment is generally believed by clinicians to be effective in alleviating signs and symptoms attributed to LPR, incontrovertible data confirming efficacy are scarce.  Confounding the issues further, there are numerous studies that purport to show that various widely used treatments are not effective, although the scientific merit of virtually all of these studies has been challenged.  The authors concluded that LPR remains a controversial diagnosis.  Treatment with PPIs persists despite weak evidence supporting or refuting their utility, and well-designed studies are needed to understand diagnosis, treatment, pathyophysiology, and long-term health consequences of LPR and its treatment.

DiFiore et al (2005) examined the temporal relationship between apnea and gastro-esophageal reflux (GER) and assessed the effect of GER on apnea duration.  A total of 119 preterm infants underwent 12-hour cardiorespiratory monitoring studies using respiratory inductance plethysmography, heart rate, oxygen saturation (SaO2), and esophageal pH.  The studies were scored for GER (pH less than 4 for greater than or equal to 5 seconds) and apnea greater than or equal to 15 seconds or greater than or equal to 10 seconds that occurred within 30 seconds of GER.  Apnea greater than or equal to 10 seconds was used to assess whether GER would prolong apnea duration.  There were a total of 6,255 episodes of GER.  Only 1 % of GER episodes were associated with apnea greater than or equal to 15 seconds, and there was no difference in apnea rate before, during, or after GER.  There was also no difference in rate of apnea greater than or equal to 10 seconds before versus during GER; however, there was a decrease in apnea rate immediately after GER.  The presence of GER during apnea did not prolong apnea duration, and GER had no effect on the lowest SaO2 or heart rate during apnea.  The authors concluded that there is no evidence of a temporal relationship between acid-based GER and apnea in preterm infants.  In addition, GER does not prolong apnea duration and does not exacerbate the resultant decrease in heart rate and SaO2.  Moreover, the 2006 summary proceedings from the Apnea Prematurity Group of the National Institutes of Child Health and Human Development (Finer et al, 2006) termed the relationship between apnea of prematurity (AOP) and GERD unsubstantiated.

Slocum et al (2007) stated that GER and AOP are both common occurrences in premature infants.  However, a causal relationship between the 2 remains controversial.  Strong physiologic evidence indicates that a variety of protective reflex responses may elicit laryngeal adduction and apnea.  Although a potential link between GER and apnea may exist through this pathway, clinical studies can be cited to either support or refute such a link in premature infants.  The majority of GER episodes do not appear to be related to apnea.  In a specific subset of events, a causal relationship may exist.  Whether this is related to the character of the reflux episode or to a predisposition in a subpopulation of infants is unclear.  The authors presented the evidence for and against an association between GER and apnea, discussed techniques used in their evaluation, and identified approaches for future investigation.

Corvaglia et al (2009) evaluated the relationship between GER detected by combined multi-channel intraluminal impedance-pH measurement and AOP in 26 preterm infants.  Although the findings showed that 154 apneas out of 1,136 were triggered by GER (p = 0.034), the authors concluded that further studies are needed to recognize clinical features that identify those patients who are more susceptible to GER-triggered apneas.

The American College of Radiology's Appropriateness Criteria on "Vomiting in infants up to 3 months of age" (Bulas et al, 2011) stated that "The role of imaging in evaluating the vomiting infant is to define whether and where there is a point of anatomic obstruction.  Secondarily, one should note whether there is GER or delayed gastric emptying.  Diagnostic studies that are complementary to imaging examinations include esophageal pH monitoring, esophageal motility studies, endoscopic evaluation of the esophagus, and multichannel intraluminal impedance".

The AGA's medical position statement on the management of Barrett's esophagus (2011) noted that "The guideline developers recommend against attempts to eliminate esophageal acid exposure (proton pump inhibitors [PPIs] in doses greater than once daily, esophageal pH monitoring to titrate PPI dosing, or antireflux surgery) for the prevention of esophageal adenocarcinoma (strong recommendation, moderate-quality evidence)".

Multichannel Intraluminal Impedance (MII) technology was designed to allow characterization of bolus movement within the esophagus regardless of the pH level. It provides 2 testing modalities in the evaluation of GERD. Esophageal function testing (EFT) combines MII with standard pressure manometry. Gastroesophageal reflux (GER) monitoring (Sleuth) combines MII with standard pH testing. Combined manometry and impedance is intended to provide an assessment of esophageal function without the need for radiation. MII with pH is intended to determine whether a patient has non-acid reflux and help to determine why a patient continues to have symptoms while on adequate medical therapy. It also is intended to sort out which patients with continuing symptoms on medical therapy do not have reflux as the cause of their symptoms. Multichannel intraluminal impedance in combination with pH monitoring in the evaluation of GERD is considered investigational/experimental because there is inadequate evidence in the peer-reviewed published clinical literature regarding its effectiveness.

CPT Codes / HCPCS Codes / ICD-9 Codes
Esophageal pH Monitoring:
CPT codes covered when selection criteria are met:
ICD-9 codes covered if selection criteria are met:
462 Acute pharyngitis
464.00 Acute laryngitis without mention of obstruction
472.1 Chronic pharyngitis
476.0 Chronic laryngitis
493.10 Intrinsic asthma, unspecified
530.81 Esophageal reflux
786.2 Cough
786.50 Chest pain, unspecified
ICD-9 code not covered for indications in the CPB:
530.11 Reflux esophagitis
530.85 Barrett's esophagus
536.2 Persistent vomiting [vomiting in infants]
770.81 - 770.82 Primary and other apnea of newborn
779.2 - 779.33 Bilious and other vomiting in newborn
787.01 Nausea with vomiting [vomiting in infants]
787.03 Vomiting alone
787.04 Bilious emesis [vomiting in infants]
Airway pH Monitoring:
There is no specific code for airway pH monitoring:
Multichannel intraluminal impedance in combination with pH monitoring:
No specific code
CPT codes not covered for indications in the CPB:
ICD-9 codes not covered for indications listed in the CPB:
530.81 Esophageal reflux

The above policy is based on the following references:
  1. American Gastroenterological Association (AGA). American Gastroenterological Association medical position statement: Guidelines on the use of esophageal pH recording. Gastroenterology. 1996;110(6):1981 (reviewed 2001).
  2. Kahrilas PJ, Quigley EMM. Clinical esophageal pH recording: A technical review for practice guideline development. Gastroenterology 1996;110:1982-1996.
  3. British Society of Gastroenterology (BSG). Guidelines for oesophageal manometry and pH monitoring. Clinical Practice Guidelines. London, UK: BSG; 1996. Available at: Accessed June 18, 2003.
  4. Pandolfino JE, Richter JE, Ours T, et al. Ambulatory esophageal pH monitoring using a wireless system. Am J Gastroenterol. 2003;98(4):740-749.
  5. DeVault KR, Castell DO and the Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. American College of Gastroenterology Treatment Guidelines. Am J Gastroenterol. 1999;94(6):1434-1442.
  6. Streets CG, DeMeester TR. Ambulatory 24-hour esophageal pH monitoring: Why, when, and what to do. J Clin Gastroenterol. 2003;37(1):14-22.
  7. Soll AH, Fass R. Gastroesophageal reflux disease: Presentation and assessment of a common, challenging disorder. Clin Cornerstone. 2003;5(4):2-14; discussion 14-17.
  8. DiMarino AJ Jr, Cohen S. Clinical relevance of esophageal and gastric pH measurements in patients with gastro-esophageal reflux disease (GERD). Curr Med Res Opin. 2005;21(1):27-36.
  9. Jiang SP, Huang LW. Role of gastroesophageal reflux disease in asthmatic patients. Eur Rev Med Pharmacol Sci. 20059(3):151-160.
  10. Irwin RS. Chronic cough due to gastroesophageal reflux disease: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1 Suppl):80S-94S.
  11. Ahlawat SK, Novak DJ, Williams DC, et al. Day-to-day variability in acid reflux patterns using the BRAVO pH monitoring system. J Clin Gastroenterol. 2006;40(1):20-24.
  12. National Institute for Health and Clinical Excellence (NICE). Catheterless oesophageal pH monitoring. Interventional Procedure Guidance 187. London, UK: NICE; July 2006.
  13. BlueCross BlueShield Association (BCBSA), Technology Evaluation Center (TEC). Special report: Wireless esophageal pH monitoring. TEC Assessment Program. Chicago, IL: BCBSA; May 2006;21(2). Available at: Accessed October 10, 2007.
  14. Dickman R, Fass R. Ambulatory esophageal pH monitoring: New directions. Dig Dis. 2006;24(3-4):313-318.
  15. Wenner J, Johnsson F, Johansson J, Oberg S. Wireless esophageal pH monitoring is better tolerated than the catheter-based technique: Results from a randomized cross-over trial. Am J Gastroenterol. 2007;102(2):239-245.
  16. Hirano I, Richter JE; Practice Parameters Committee of the American College of Gastroenterology. ACG practice guidelines: Esophageal reflux testing. Am J Gastroenterol. 2007;102(3):668-685.
  17. Semeniuk J, Kaczmarski M. 24-hour esophageal pH-monitoring in children suspected of gastroesophageal reflux disease: Analysis of intraesophageal pH monitoring values recorded in distal and proximal channel at diagnosis. World J Gastroenterol. 2007;13(38):5108-5115.
  18. Croffie JM, Fitzgerald JF, Molleston JP, et al. Accuracy and tolerability of the Bravo catheter-free pH capsule in patients between the ages of 4 and 18 years. J Pediatr Gastroenterol Nutr. 2007;45(5):559-563.
  19. Davids T, Sommer DD, Armstrong D. Survey of current perspectives on laryngopharyngeal reflux among Canadian otolaryngologists. J Otolaryngol Head Neck Surg. 2008;37(2):196-202.
  20. Ali Mel-S. Laryngopharyngeal reflux: Diagnosis and treatment of a controversial disease. Curr Opin Allergy Clin Immunol. 2008;8(1):28-33.
  21. Gupta R, Sataloff RT. Laryngopharyngeal reflux: Current concepts and questions. Curr Opin Otolaryngol Head Neck Surg. 2009;17(3):143-148.
  22. Lacy BE, Edwards S, Paquette L, et al. Tolerability and clinical utility of the Bravo pH capsule in children. J Clin Gastroenterol. 2009;43(6):514-519.
  23. Monkemüller K, Neumann H, Fry LC, et al. Catheter-free pH-metry using the Bravo capsule versus standard pH-metry in patients with non-erosive reflux disease (NERD). Z Gastroenterol. 2009;47(4):351-356.
  24. Di Fiore JM, Arko M, Whitehouse M, et al. Apnea is not prolonged by acid gastroesophageal reflux in preterm infants. Pediatrics. 2005;116(5):1059-1063.
  25. Finer NN, Higgins  R, Kattwinkel J, Martin RJ. Summary proceedings from the Apnea-of-Prematurity Group. Pediatrics. 2006;117(Supplement 1):S47-S51. 
  26. Slocum C, Hibbs AM, Martin RJ, Orenstein SR. Infant apnea and gastroesophageal reflux: A critical review and framework for further investigation. Curr Gastroenterol Rep. 2007;9(3):219-224.
  27. Corvaglia L, Zama D, Gualdi S, et al. Gastro-oesophageal reflux increases the number of apnoeas in very preterm infants. Arch Dis Child Fetal Neonatal Ed. 2009;94(3):F188-F192.
  28. Pilic D, Frohlich T, Noh F, et al. Detection of gastroesophageal reflux in children using combined multichannel intraluminal impedance and pH measurement: Data from the German Pediatric Impedance Group. J Pediatr. 2011;158(4):650-654.
  29. Bulas D, McGrane SL, Coley BD, et al, Expert Panel on Pediatric Imaging. ACR Appropriateness Criteria® vomiting in infants up to 3 months of age. [online publication]. Reston (VA): American College of Radiology (ACR); 2011. Available at: Accessed July 9, 2012.
  30. American Gastroenterological Association, Spechler SJ, Sharma P, Souza RF, et al. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 2011;140(3):1084-1091. Available at: Accessed July 9, 2012.
  31. Blanco FC et al. Pediatric gastroesophageal reflux disease. Surgical Clinics of North America, Volume 92, Issue 3  2012.
  32. Cappell MS. Clinical presentation, diagnosis, and management of gastroesophageal reflux disease. Medical Clinics of North America, Vol 89 Num 2  2005.
  33. Carroll TL et al. pH Impedance and high-resolution manometry in laryngopharyngeal reflux disease high-dose proton pump inhibitor failures. Laryngoscope, 122(11): 2473-81 2012.
  34. Castell DO et al. Non-acid gastroesophageal reflux: documenting its relationship to symptoms using multichannel intraluminal impedance (MII). Trans Am Clin Climatol Assoc, 116(): 321-33; discussion 333-4  2005.
  35. Castell DO; Vela M. Combined multichannel intraluminal impedence and ph-metry: an evolving technique to measure type and proximal extent of esophageal reflux. The American Journal of Medicine, Vol 111 Number Suppl 8A   2001.
  36. Condino AA et al. Evaluation of infantile acid and nonacid gastroesophageal reflux using combined pH monitoring and impedance measurement. J Pediatr Gastroenterol Nutr, 42(1): 16-21  2006.
  37. Cresi F et al. Prognostic values of Multichannel Intraluminal Impedance and pH monitoring in newborns with symptoms of gastroesophageal reflux disease. Journal of Pediatrics, Volume 162, Issue 4  2013.
  38. Dalby K et al. Reproducibility of 24-hour combined multiple intraluminal impedance (MII) and pH measurements in infants and children. Evaluation of a diagnostic procedure for gastroesophageal reflux disease. Dig Dis Sci, 52(9): 2159-65  2007.
  39. Del Genio et al. Prospective assessment of patient selection for antireflux surgery by combined multichannel intraluminal impedance pH monitoring. J Gastrointest Surg, 12(9): 1491-6  2008.
  40. Di Pace MR et al. Evaluation of esophageal motility and reflux in children treated for congenital diaphragmatic hernia with the use of combined multichannel intraluminal impedance and pH monitoring. J Pediatr Surg, 46(10): 1881-6  2011.
  41. Di Pace MR et al. Evaluation of esophageal motility and reflux in children treated for esophageal atresia with the use of combined multichannel intraluminal impedance and pH monitoring. J Pediatr Surg, 46(3): 443-51  2011.
  42. Di Pace MR et al. Evaluation of esophageal motility using multichannel intraluminal impedance in healthy children and children with gastroesophageal reflux. J Pediatr Gastroenterol Nutr, 52(1): 26-30  2011.
  43. Fike FB et al. Utility of pH/multichannel intraluminal impedance probe in identifying operative patients in infants with gastroesophageal reflux disease. J Laparoendosc Adv Surg Tech A, 22(5): 518-20  2012.
  44. Francavilla R et al. Comparison of esophageal pH and multichannel intraluminal impedance testing in pediatric patients with suspected gastroesophageal reflux. J Pediatr Gastroenterol Nutr, 50(2): 154-60  2010.
  45. Gawron AJ et al. Many patients continue using proton pump inhibitors after negative results from tests for reflux disease. Clin Gastroenterol Hepatol, 10(6): 620-5; quiz e57  2012.
  46. Hajar N et al. Impedance pH confirms the relationship between GERD and BMI. Dig Dis Sci, 57(7): 1875-9  2012.
  47. Hila A et al. Combined multichannel intraluminal impedance and pH esophageal testing compared to pH alone for diagnosing both acid and weakly acidic gastroesophageal reflux. Clin Gastroenterol Hepatol, 5(2): 172-7  2007.
  48. Kline MM et al. The utility of intraluminal impedance in patients with gastroesophageal reflux disease-like symptoms but normal endoscopy and 24-hour pH testing. Clin Gastroenterol Hepatol, 6(8): 880-5; quiz 836 2008.
  49. Loots CM et al. Interobserver and intraobserver variability in pH-impedance analysis between 10 experts and automated analysis. Journal of Pediatrics, Volume 160, Issue 3  2012.
  50. Loots CM et al. Addition of pH-impedance monitoring to standard pH monitoring increases the yield of symptom association analysis in infants and children with gastroesophageal reflux. J Pediatr, 154(2): 248-52  2009.
  51. Malhotra A et al. Use of pH-impedance testing to evaluate patients with suspected extraesophageal manifestations of gastroesophageal reflux disease. J Clin Gastroenterol, 42(3): 271-8  2008.
  52. Mattioli G et al. Esophageal impedance/pH monitoring in pediatric patients: preliminary experience with 50 cases. Dig Dis Sci, 51(12): 2341-7  2006.
  53. Pandolfino JE; Vela MF. Esophageal-reflux monitoring. Gastrointestinal Endoscopy, Vol 69 Iss 4  2009.
  54. Park W; Vaezi MF. Esophageal impedance recording: clinical utility and limitations. Curr Gastroenterol Rep; 7(3): 182-9  2005.
  55. Pilic D e al. Detection of gastroesophageal reflux in children using combined multichannel intraluminal impedance and pH measurement: Data from the German Pediatric Impedance Group. Journal of Pediatrics, Volume 158, Issue 4  2011.
  56. Pleskow DK et al. Esophageal function testing. Gastrointestinal Endoscopy - Volume 76, Issue 2 (August 2012.
  57. Rosen R et al. Does reflux monitoring with multichannel intraluminal impedance change clinical decision making? J Pediatr Gastroenterol Nutr, 52(4): 404-7  2011.
  58. Rosen R et al. The sensitivity of multichannel intraluminal impedance and the pH probe in the evaluation of gastroesophageal reflux in children. Clin Gastroenterol Hepatol, 4(2): 167-72  2006.
  59. Shay SS et al. Multichannel intraluminal impedance accurately detects fasting, recumbent reflux events and their clearing. Am J Physiol Gastrointest Liver Physiol. 283(2): G376-83  2002.
  60. Tutuian R; Castell DO. Reflux monitoring: role of combined multichannel intraluminal impedance and pH. Gastrointest Endosc Clin N Am, 15(2): 361-71  2005.
  61. Villa N; Vela MF. Impedance-pH testing. Gastroenterology Clinics, Volume 42, Issue 1  2013.
  62. Wenzl TG  et al. Indications, methodology, and interpretation of combined esophageal impedance-pH monitoring in children: ESPGHAN EURO-PIG standard protocol. J Pediatr Gastroenterol Nutr, 55(2): 230-4  2012.
  63. Woodley FW; Mousa H. Acid gastroesophageal reflux reports in infants: a comparison of esophageal pH monitoring and multichannel intraluminal impedance measurements. Dig Dis Sci, 51(11): 1910-6  2006.

email this page   

Copyright Aetna Inc. All rights reserved. Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.
Back to top